We found that high ARHGAP11A level was positively associated with expression of inhibitory ICs in ccRCC patients (Figure 7A), suggesting a potential role of ARHGAP11A level in immunotherapy effectiveness prediction. Here, ARHGAP11A is linked to nonpapillary renal cell carcinoma.